NT
Intellia Therapeutics, Inc.
NTLA · NASDAQ
$11.75 -4.24% (-$0.52)
1M -10.37%
Market Cap $1.70B
P/E Ratio -
Div. Yield -
ROE 57.79%
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/S 28.55x
P/B 2.33x
P/E N/A
Growth
49 /100
Stable Rev. growth 9.09%
Book val. growth 18.40%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 46.48%
FCF margin 783.30%
Net margin 672.16%
Quality
1 /100
Poor ROIC 52.86%
Asset turnover 0.07x
ROE 57.79%
Debt
100 /100
Low Debt/Equity 0.10x
Current ratio 6.65x
Int. coverage N/A
Stability
33 /100
Unstable Beta 1.82x
Profitable years 0
Rev. volatility 45.00%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o NTLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Leonard
Employees
377
Headquarters
Cambridge
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report